The authors concluded that cost-effectiveness analysis supports testing for EGFR mutations in patients with Stage IV or recurrent lung adenocarcinomas, performing rebiopsy if insufficient tissue is available for testing and treating patients with EGFR mutations with erlotinib as a first-line therapy. Here, EGFR is linked to lung adenocarcinoma.